Regulacje i polityka gospodarcza · 30/11/1998
NIH Seeks Licensee(s) or CRADA for Therapeutic Treatment of Lymphomas and Leukemias with RFB4(dsFv)-PE38
The National Institutes of Health (NIH) is seeking a partner to further develop, evaluate, and commercialize RFB4(dsFv)-PE38, a recombinant immunotoxin targeting CD22-positive B-cells, for the treatment of lymphomas and leukemias.